Welcome to our dedicated page for Bolt Biotherapeutics news (Ticker: BOLT), a resource for investors and traders seeking the latest updates and insights on Bolt Biotherapeutics stock.
Bolt Biotherapeutics, Inc. (Nasdaq: BOLT) is a clinical-stage biopharmaceutical company developing novel immunotherapies for cancer, and its news flow reflects the progress and challenges of advancing a pipeline in oncology. Company updates frequently highlight developments in its lead programs, including BDC-3042, a first-in-class agonist antibody targeting dectin-2 on tumor-associated macrophages, and BDC-4182, a next-generation Boltbody ISAC clinical candidate targeting claudin 18.2.
On this page, readers can follow BOLT news related to clinical trial milestones, preclinical data presentations, and collaboration activities. Press releases have detailed Phase 1 dose-escalation results for BDC-3042 in patients with advanced solid tumors, including safety, pharmacokinetics, and early signs of anti-tumor activity. Other announcements describe the opening and conduct of the BDC-4182 Phase 1 study in gastric and gastroesophageal cancer, protocol updates such as the introduction of step-up dosing, and expectations for future clinical data readouts as disclosed by the company.
News items also cover preclinical Boltbody ISAC programs targeting CEA and PD-L1, with data presented at major scientific meetings like the American Association for Cancer Research (AACR) and the Society for Immunotherapy of Cancer (SITC). These releases summarize findings such as complete tumor regressions in animal models, induction of immunological memory, and favorable toxicology profiles in non-human primates.
In addition, Bolt Biotherapeutics issues regular financial results and business updates, including quarterly and annual earnings releases, cash runway commentary, and information about restructuring actions intended to reduce operating expenses. Collaboration updates with partners such as Genmab and Toray, as well as participation in investor and scientific conferences, are also common topics. Investors and observers can use this news feed to track how Bolt Biotherapeutics’ clinical, preclinical, and corporate activities evolve over time.
Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company, is set to present at the 20th Annual Needham Virtual Healthcare Conference on April 15, 2021, at 10:15 AM ET. CEO Randall C. Schatzman, Ph.D., will provide an overview of the company. Bolt is pioneering immuno-oncology agents, specifically Boltbody™ Immune-stimulating Antibody Conjugates (ISACs), which aim to convert ‘cold’ tumors to ‘hot’ tumors. Their lead candidate, BDC-1001, targets HER2-expressing solid tumors and is currently in phase 1/2 clinical testing.
Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) reported strong fundraising outcomes, raising $358 million through an upsized IPO and Series C financing. The company announced positive preliminary results from its Phase 1/2 trial of BDC-1001, targeting HER2-expressing solid tumors, showing clinical activity in 20 treated patients. R&D expenses increased to $40.4 million in 2020 from $26 million in 2019. Despite a reported loss from operations of $49.2 million for the year, the company maintains a strong cash position to fund operations into 2023.
Bolt Biotherapeutics, Inc. (Nasdaq: BOLT) has successfully closed its initial public offering, selling 13,225,000 shares at $20.00 each. This includes the full exercise of the underwriters' option for an additional 1,725,000 shares. The company specializes in developing immune-oncology therapies, particularly its lead candidate BDC-1001, aimed at HER2-expressing solid tumors. The offering was managed by Morgan Stanley, SVB Leerink, Stifel, and Guggenheim Securities.